← ANALYST RATINGS · TIPRANKS
Solid Biosciences (SLDB): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $20.57, the highest $26.00, the lowest $14.00. The average is +272.0% from the last price of $5.53.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Buy | — | Reiterated | 15.10.26on TipRanks 08:10 | +4.7%next day −2.6% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $20.00 | Buy | +261.7% | Initiated | 14.10.26on TipRanks 19:50 | +4.7%next day −2.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.00 → $5.50−21.4% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.00 → $5.50−21.4% | Sell | −0.5% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.00 → $5.50−21.4% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $5.50−15.4% | Sell | −0.5% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.00 → $5.50−21.4% | Hold | −0.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.00 → $5.50−21.4% | Sell | −0.5% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $7.00−6.7% | Hold | +26.6% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $6.50−7.1% | Hold | +17.5% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.00 → $7.50+7.1% | Hold | +35.6% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $7.00+7.7% | Hold | +26.6% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $7.00−6.7% | Hold | +26.6% | Reiterated | 03.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $6.50−7.1% | Hold | +17.5% | Reiterated | 03.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $7.00−6.7% | Hold | +26.6% | Reiterated | 03.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $7.00−6.7% | Hold | +26.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $7.00−6.7% | Hold | +26.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $7.00−6.7% | Hold | +26.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $18.00 | Buy | +225.5% | Reiterated | 30.09.26on TipRanks 07:55 | +1.2%next day −3.6% · 5 days −7.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 | Hold | +35.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 | Hold | +35.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 | Hold | +35.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 | Hold | +26.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 | Hold | +35.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 | Hold | +35.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $20.00 | Buy | +261.7% | Reiterated | 16.09.26on TipRanks 08:55 | +4.6%next day +0.6% · 5 days −10.1% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $18.00 | Buy | +225.5% | Initiated | 16.09.26on TipRanks 06:15 | +4.6%next day +0.6% · 5 days −10.1% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $26.00 | Buy | +370.2% | Reiterated | 15.09.26on TipRanks Sep 16 08:55 | −3.8%next day +4.6% · 5 days +4.2% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $25.00 | Buy | +352.1% | Reiterated | 14.09.26on TipRanks 06:35 | +0.9%next day −3.8% · 5 days −4.2% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $14.00 | Buy | +153.2% | Reiterated | 10.09.26on TipRanks Sep 11 06:10 | −4.3%next day −4.9% · 5 days −2.8% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $16.00 → $20.00+25.0% | Buy | +261.7% | Initiated | 21.08.26on TipRanks 07:35 | +1.8%next day −1.2% · 5 days +4.6% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $11.00 | Buy | +98.9% | Reiterated | 11.08.26on TipRanks 07:55 | +3.7%next day +2.2% · 5 days +3.0% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $19.00 | Buy | +243.6% | Reiterated | 07.08.26on TipRanks 02:35 | −4.3%next day +2.1% · 5 days +9.3% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 22:31 | −4.3%next day +2.1% · 5 days +9.3% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $16.00 | Buy | +189.3% | Reiterated | 18.05.26on TipRanks May 13 08:35 | −5.0%next day +2.6% · 5 days −12.2% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $15.00 | Buy | +171.2% | Reiterated | 13.05.26on TipRanks 16:10 | +2.6%next day −8.1% · 5 days −14.1% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $26.00 | Buy | +370.2% | Initiated | 20.03.26on TipRanks 06:35 | +0.2%next day +0.5% · 5 days +3.4% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $10.00 → $9.00−10.0% | Buy | +62.7% | Reiterated | 03.11.25on TipRanks Nov 4 03:20 | −3.7%next day −14.2% · 5 days −19.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Solid Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.00 at a price of $7.23 (+162.8%); now: $20.00 at $5.53 (+261.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 10 | 10 | 8 | 10 | 10 |
| Buy | 4 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.41 (from $-0.53 to $-0.32). Last quarter: $-0.38.
Best top-analyst consensus in the sector · Healthcare
About Solid Biosciences
- CEO: Alexander G. Cumbo
- Employees: 121
- 500 Rutherford Avenue, Charlestown, MA, 02129, US
- www.solidbio.com
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 7 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗